Physician profile
Anish Kumar Ray
NPI 1609024256
$164,359.39
in general payments reported to CMS, 2019-2025
13 companies · $18K in 2025
The $18K reported for 2025 was more than what 90% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $19K · 2021: $23K · 2022: $31K · 2023: $25K · 2024: $31K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $17K · Consulting Fee: $7,325 · Food and Beverage: $2,217 · Honoraria: $400 · Education: $47.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,146.00 |
| Travel and Lodging | $17,021.23 |
| Consulting Fee | $7,325.00 |
| Food and Beverage | $2,216.73 |
| Honoraria | $400.00 |
| Education | $47.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $97,897.70 | 2020-2025 | |
| Btg International INC. | $65,250.22 | 2019-2025 | Voraxaze |
| Beone Medicines LTD. | $500.00 | 2025 | |
| Stryker Corporation | $340.00 | 2025 | |
| Tempus Ai, INC | $138.24 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.91 | 2022 | |
| Foundation Medicine, INC. | $43.15 | 2023 | |
| Jazz Pharmaceuticals INC. | $36.52 | 2025 | |
| Seagen INC. | $17.63 | 2023 | Adcetris |
| Adaptive Biotechnologies Corporation | $16.83 | 2024 | Clonoseq |
| Amgen INC. | $16.19 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.